Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxDecipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/in Retrospective studies/by MaxThe Promise of In Vivo CAR T Cell Therapies
/in Not PCa related/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/in Oncolytic, Preclinical Research/by MaxPSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial
/in Post-hoc/by MaxAlpha DaRT: A Promising Frontier in the Treatment of Prostate, Bladder, and Advanced Cancers
/in Clinical Trial, Localized, Metastatic/by MaxStatins Linked to Improved Survival in Advanced Prostate Cancer Patients on Apalutamide
/in Post-hoc, Retrospective studies/by Max